-
公开(公告)号：US20130034581A1
公开(公告)日：2013-02-07
申请号：US13304175
申请日：2011-11-23
申请人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
发明人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
-
公开(公告)号：US20240309314A1
公开(公告)日：2024-09-19
申请号：US18508109
申请日：2023-11-13
申请人： Genentech, Inc.
发明人： Masaru Ken SHIRATORI , Robert David KISS , Hardayal PRASHAD , Raquel IVERSON , Justin BOURRET , Michael KIM , Salim CHARANIYA
CPC分类号： C12N1/36 , C12N7/00 , C12N2750/14061 , C12N2760/12061 , C12N2760/16061 , C12N2760/18061 , C12N2760/20061 , C12N2770/16061 , C12N2770/32061 , C12N2770/36061
摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
-
公开(公告)号：US20180369363A1
公开(公告)日：2018-12-27
申请号：US16126791
申请日：2018-09-10
申请人： Icahn School of Medicine at Mount Sinai , St. Jude Children's Research Hospital , The United States of America, As Represented by the Secretary of Agriculture
发明人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
IPC分类号： A61K39/145 , C12N7/00 , A61K39/12 , A61K39/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
-
公开(公告)号：US20150273049A1
公开(公告)日：2015-10-01
申请号：US14636651
申请日：2015-03-03
申请人： Icahn School of Medicine at Mount Sinai , St. Jude Children's Research Hospital , The United States of America, As Represented by the Secretary of Agriculture
发明人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
IPC分类号： A61K39/145 , C12N7/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
摘要翻译： 本发明通常涉及具有拮抗细胞干扰素（IFN）应答的能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 特别地，本发明涉及具有修饰猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。
-
15.发明授权Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof 有权能够中和流感病毒H5N1的人结合分子及其用途公开(公告)号：US09109017B2
公开(公告)日：2015-08-18
申请号：US14043677
申请日：2013-10-01
申请人： Crucell Holland B.V.
IPC分类号： A61K39/395 , A61K39/42 , C07K16/10 , A61K47/48 , A61K39/00
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N2760/00011 , C12N2760/00061 , C12N2760/16011 , C12N2760/16061 , C12N2760/16111 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
摘要翻译： 描述了结合分子，例如结合流感病毒H5N1的人单克隆抗体，并具有针对流感病毒H5N1的中和活性。 还描述了编码抗体的核酸分子和包含抗体的组合物以及鉴定或产生抗体的方法。 抗体可用于诊断，预防和/或治疗流感病毒H5N1感染。 在某些实施方案中，抗体在体内提供跨亚型保护，使得可以预防和/或治疗H5，H2，H6，H9和H1基于流感亚型的感染。
-
公开(公告)号：US09011848B2
公开(公告)日：2015-04-21
申请号：US13458964
申请日：2012-04-27
IPC分类号： A61K39/395 , A61K39/00 , A61K39/42 , C07K16/10 , A61K47/48
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N2760/00011 , C12N2760/00061 , C12N2760/16011 , C12N2760/16061 , C12N2760/16111 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
-
公开(公告)号：US08999352B2
公开(公告)日：2015-04-07
申请号：US13304175
申请日：2011-11-23
申请人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
发明人： Peter Palese , Adolfo Garcia-Sastre , Richard J. Webby , Juergen A. Richt , Robert G. Webster , Kelly M. Lager
IPC分类号： A61K39/145 , A61K49/00 , C12N7/00 , A61K39/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
摘要翻译： 本发明通常涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 特别地，本发明涉及具有修饰猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。
-
公开(公告)号：US20130344570A1
公开(公告)日：2013-12-26
申请号：US13844051
申请日：2013-03-15
申请人： GENENTECH, INC.
发明人： Masaru Ken SHIRATORI , Robert David KISS , Hardayal PRASHAD , Raquel IVERSON , Justin BOURRET , Michael KIM , Salim CHARANIYA
CPC分类号： C12N1/36 , C12N7/00 , C12N2750/14061 , C12N2760/12061 , C12N2760/16061 , C12N2760/18061 , C12N2760/20061 , C12N2770/16061 , C12N2770/32061 , C12N2770/36061
摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
摘要翻译： 本发明提供使用高温短时间（HTST）处理和调整各种参数的病毒灭活方法，使得沉淀物的产生和沉淀的沉积减少和/或最小化。
-
19.发明授权Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof 有权能够中和流感病毒h5n1的人结合分子及其用途公开(公告)号：US08192927B2
公开(公告)日：2012-06-05
申请号：US12310812
申请日：2007-09-06
IPC分类号： C07K16/08 , C07K16/00 , C12Q1/70 , A61K39/395 , C12K16/00
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12N2760/00011 , C12N2760/00061 , C12N2760/16011 , C12N2760/16061 , C12N2760/16111 , G01N33/56983 , G01N2333/11 , G01N2469/10
摘要： The present invention relates to binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. The disclosure provides nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H5N1 infection. In a preferred embodiment, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9 and H1-based influenza subtypes can be prevented and/or treated.
摘要翻译： 本发明涉及结合分子，例如与流感病毒H5N1结合并具有针对流感病毒H5N1的中和活性的人单克隆抗体。 本公开提供编码抗体的核酸分子，其序列和包含抗体的组合物以及鉴定或产生抗体的方法。 抗体可用于诊断，预防和/或治疗流感病毒H5N1感染。 在优选的实施方案中，抗体在体内提供交叉亚型保护，从而可以预防和/或治疗以H5，H2，H6，H9和H1为基础的流感亚型的感染。
-
公开(公告)号：US07758868B2
公开(公告)日：2010-07-20
申请号：US11963930
申请日：2007-12-24
CPC分类号： C12N9/1241 , A61K39/00 , A61K2039/5254 , C12N7/00 , C12N2740/16061 , C12N2760/16061 , C12N2770/32661 , Y02A50/466
摘要： The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed.
摘要翻译： 本发明包括与在聚合酶的保守区域具有一个或多个不同氨基酸取代的病毒聚合酶有关的组合物和方法产生具有不同的复制率和保真度的酶。 公开了用于生产减毒病毒和抗病毒疫苗的普遍适用的基于聚合酶机制的策略。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.056 秒)
